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Postoperative nausea and vomiting (PONV) is one of the most common and undesirable
complaints recorded in as many as 70–80% of high-risk surgical patients. The current
prophylactic therapy recommendations for PONV management stated in the Society of
Ambulatory Anesthesia (SAMBA) guidelines should start with monotherapy and patients
at moderate to high risk, a combination of antiemetic medication should be considered.
Consequently, if rescue medication is required, the antiemetic drug chosen should
be from a different therapeutic class and administration mode than the drug used for
prophylaxis. The guidelines restrict the use of dexamethasone, transdermal scopolamine,
aprepitant, and palonosetron as rescue medication 6 h after surgery. In an effort to ﬁnd
a safer and reliable therapy for PONV, new drugs with antiemetic properties and minimal
side effects are needed, and scopolamine may be considered an effective alternative.
Scopolamine is a belladonna alkaloid, α-(hydroxymethyl) benzene acetic acid 9-methyl-
3-oxa-9-azatricyclo non-7-yl ester, acting as a non-selective muscarinic antagonist and
producing both peripheral antimuscarinic and central sedative, antiemetic, and amnestic
effects. The empirical formula is C17H21NO4 and its structural formula is a tertiary amine
L-(2)-scopolamine (tropic acid ester with scopine; MW = 303.4). Scopolamine became the
ﬁrst drug commercially available as a transdermal therapeutic system used for extended
continuous drug delivery during 72 h. Clinical trials with transdermal scopolamine have
consistently demonstrated its safety and efﬁcacy in PONV. Thus, scopolamine is a
promising candidate for the management of PONV in adults as a ﬁrst line monotherapy or
in combination with other drugs. In addition, transdermal scopolamine might be helpful in
preventing postoperative discharge nausea and vomiting owing to its long-lasting clinical
effects.
Keywords: nausea, vomiting, antiemetic, postoperative, prophylaxis, transdermal scopolamine, pharmacokinetics,
pharmacodynamics
INTRODUCTION
Postoperative nausea and vomiting (PONV) are among the most
common complaints from patients and clinicians (Jones et al.,
2006; Sood et al., 2007). Prevention and treatment of PONV
is a key patient care component capable of alleviating patient
discomfort, distress, and dissatisfaction during the postopera-
tive period. PONV per se is a signiﬁcant complication that may
lead to other postoperative adverse events including aspiration,
pneumonitis, dehydration, wound dehiscence, acid-base disor-
ders, and electrolyte imbalance, hematoma formation, esophageal
rupture, increases in intraocular and/or intracranial pressures,
and acute blood pressure elevations (Fabling et al., 2000; Lipp
and Kaliappan, 2007; Feng et al., 2009). According to Society of
Ambulatory Anesthesia (SAMBA) Consensus Guidelines for the
Management of PONV, the incidence of PONV is between 20–
30% among all patients undergoing surgery.With no prophylactic
therapy, PONV occurs in as many as 70–80% of high-risk patients
undergoing surgery (Gan et al., 2014). Three categories of baseline
risk factors: patient-speciﬁc, anesthetic, and surgical, are indepen-
dent predictors of PONV, and may be helpful in selecting the
right candidates for prophylaxis. The most prevalent patient and
anesthesia related risk factors for PONV are female gender, non-
smoking status, postoperative opioid consumption, and a history
of PONV/postoperative discharge nausea and vomiting (PDNV)
or motion sickness (Apfel et al., 1999). Each factor has a punc-
tuation value of 1, which, when added, will equal 0–4. When 0,
1, 2, 3, or 4 of the above mentioned independent predictors are
present; the corresponding risk for PONV is approximately 10,
20, 40, 60, or 80%, respectively (Gan and Habib, 2003; Gan et al.,
2014). Presence of a single risk factor corresponds to a 20% risk
of PONV, while combination of all the risk factors will be related
to an 80% chance of PONV (Apfel et al., 1999). The SAMBA Con-
sensus Guidelines for theManagement of PONV include assessing
the patient’s risk, reducing the baseline risk factors, and providing
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prophylactic treatment. The current (Gan et al., 2014) prophy-
lactic therapy recommendations for PONV management stated
in the SAMBA guidelines should start with monotherapy and
patients at moderate to high risk, a combination of antiemetic
medication should be considered. Consequently, if rescue medi-
cation is required, the antiemetic drug chosen should be from a
different therapeutic class and administrationmode than the drug
used for prophylaxis. Considering the increasing rate of outpatient
surgeries, long-lasting prophylactic antiemetic therapeutic efforts
may be beneﬁcial for postoperative patient care and improve the
outcomes. Scopolamine is a long-acting prophylactic antiemetic
(72 h) approved in 1979 by the Food and Drug Administration
(FDA; Apfel et al., 2010) as a method of preventing motion sick-
ness and, since 2001 – for prevention of PONV. In outpatient
surgical patients, PDNV usually remains unrecorded because of
early discharge, despite the fact that the patients report this com-
plication as themost undesirable postoperative event. Thus, taking
into account the beneﬁcial effects of scopolamine, its favorable
pharmacokinetic and pharmacodynamic proﬁle, and importance
of PONV prophylaxis, transdermal delivery system (TDS) may
become a strong candidate as a ﬁrst-line prophylactic medication
in perioperative care (Pergolizzi et al., 2012).
OVERVIEW OF SCOPOLAMINE
Scopolamine is a non-polar, belladonna alkaloid, α-
(hydroxymethyl) benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo
non-7-yl ester. The empirical formula is C17H21NO4 and its struc-
tural formula is a tertiary amine L-(2)-scopolamine. It is a viscous
liquid that has amolecularweight of 303.35 andapKaof 7.55–7.81.
Scopolamine is a high-afﬁnity selective competitive antagonist
of G protein-coupled muscarinic receptor for acetylcholine with
both, peripheral and central antimuscarinic effects, including
sedative, antiemetic, and amnesic action (Pergolizzi et al., 2011).
It acts on the central nervous system (CNS) by blocking choliner-
gic transmission from vestibular nuclei to higher CNS centers and
from the reticular formation to the vomiting center (Renner et al.,
2005; Package Insert, 2006). Scopolamine is available as an oral
tablet, injectable solution, and TDS. However, the oral and/or par-
enteral routes of administration are rarely used due to pronounced
dose-dependent side effects (excessive sedation, agitation, halluci-
nations, vertigo, dry mouth, and drowsiness) and a short plasma
half-life.
TRANSDERMAL SCOPOLAMINE: PHARMACOKINETICS AND
PHARMACODYNAMIC PROPERTIES
Transdermal delivery system (TDS) delivery system (patch) func-
tions as a long-acting prophylactic antiemetic (72 h). It is a 0.2mm
thick and 2.5 cm2 ﬁlm,with four layers (Pergolizzi et al., 2012). The
ﬁrst layer of the patch is a tancolored aluminized polyester ﬁlm.
The second layer is a drug reservoir mixture of scopolamine, light
mineral oil, and polyisobutylene. The third layer represents a dose
delivery rate controlling microporous polypropylene membrane,
and the fourth layer is an adhesive surface formulation of mineral
oil, polyisobutylene, and priming dose of scopolamine applied
directly to the skin (Nachum et al., 2006; Package Insert, 2006).
Only the active drug scopolamine is being released from the deliv-
ery system during the TDS application. This patch is designed for
continuous release of scopolamine following application to the
skin, with the highest permeation rate in the postauricular (mas-
toid) area, and the lowest permeation in the thigh, higher in the
forearm, and still higher in the stomach, chest and back (Pergolizzi
et al., 2011).
The TDS contains 1.5 mg of the drug in a reservoir designed
to provide a continuous slow release of scopolamine through
intact skin during the ﬁrst 72 h of patch application (Pergolizzi
et al., 2011). The priming dose of scopolamine (140 μg), when
applied to the post-auricular area, increases the plasma detectable
levels are reached within 4 h with a peak level at 24 h. The
rate of scopolamine release after the patch application equals
0.5 mg/day of scopolamine over a 3 days period. The average
plasma concentration produced is 87 pg/mL for free scopolamine
and 354 pg/mL for total scopolamine (free fraction and conjugated
drug; Package Insert, 2006). After removal of the used system,
plasma scopolamine levels decrease gradually with an elimina-
tion half-life of 9.5 h (Pergolizzi et al., 2011). Upon absorption,
scopolamine is mostly bound to plasma proteins and undergoes
an almost complete hepatic elimination via hepatic conjugation
with subsequent urinary excretion of hydrophilic metabolites.
Less than 5% of scopolamine is excreted unchanged (Renner
et al., 2005; Nachum et al., 2006). Like atropine, scopolamine
acts as a non-speciﬁc competitive antagonist of acetylcholine
at muscarinic receptors. Due to receptor sensitivity, the inhi-
bition of salivation (M3 receptors) can be reached at lower
doses, whereas much higher doses are needed to induce car-
diac effects (M2 receptors). As a result, the measured plasma
scopolamine concentration does not necessarily correlate with
the extent of pharmacodynamic effects of the drug. Scopo-
lamine pharmacodynamics only quantitatively differs from that
of atropine. Whereas atropine has almost no detectable effects
on CNS in clinically applicable doses, scopolamine exerts promi-
nent CNS effects at low therapeutic doses. This difference may
be explained by a better penetration of scopolamine through the
blood brain barrier. Adverse effects associated with the use of
scopolamine can, in the majority of cases, be attributed to an
extension of its pharmacodynamic effects, and result from exces-
sive anticholinergic activity (Renner et al., 2005; Nachum et al.,
2006).
The commonest side effects reported for scopolamine therapy
are sedation, dry mouth, blurry vision, central cholinergic syn-
drome, and confusion (Apfel et al., 2010). Scopolamine produces
mydriasis and cycloplegia by paralyzing the sphincter muscle of
the iris and the ciliary muscle of the lens. These effects on eye may
last up to 7–12 days after a topical application of scopolamine.
Although, systematically administered scopolamine has little effect
on the intraocular pressure, patients with narrow-angle glaucoma
may develop dangerous increases in the intraocular pressure fol-
lowing scopolamine (Renner et al., 2005). Additional side effects
include reduction of gastric secretions and salivation, decreases
in smooth muscle tone in the gastrointestinal tract, leading to a
hypomotility, dryness of the nasopharynx, mouth, bronchi, and
bronchioli. Following smoothmuscle relaxation after scopolamine
administration, the airway resistance in the respiratory tract is
reduced. The drug exerts a similar relaxing effect on the smooth
muscle tone of urethra and bladder (Renner et al., 2005).
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CLINICAL EFFICACY
Transdermal delivery system patches have proved to be highly
effective in the management of motion sickness and PONV. This
is also supported by experimental data and studies on human vol-
unteers, showing a higher efﬁcacy of TDS compared to placebo
(Table 1; Graybiel, 1979; Graybiel et al., 1981, 1982; Dahl et al.,
1984; Shojaku et al., 1993). Kotelko et al. (1989) studied patients
undergoing elective cesarean delivery under epidural anesthesia
with the addition of epidural morphine for postoperative anal-
gesia. They reported a signiﬁcant reduction in nausea, vomiting,
and retching when comparing the TDS group vs. placebo dur-
ing the study period of 2–10 h after surgery. Additionally, the
TDS group required less antiemetic medication during the ﬁrst
24 postoperative hours. The adverse effects experienced by the
patients in both groups were dizziness (8%), blurred vision (4%
in TDS group vs. 2% placebo group) and disorientation (1% TDS
group vs. none in the placebo group). As it was shown, side
effects were minimal in both groups (Kotelko et al., 1989). Har-
nett et al. (2007) carried out a similar study in women undergoing
cesarean delivery under spinal anesthesia and induced opioid anal-
gesia to compare the effects of TDS, placebo, and ondansetron on
PONV. They administered antiemetic prophylaxis after clamping
the umbilical cord instead of applying the TDS before surgery as
Kotelko et al. (1989) reported. This relevant difference should be
considered in order to avoid potential exposure of the fetus and
consequent side effects. Their results showed that TDS was signiﬁ-
cantly superior to ondansetron or placebo as a PONVprophylactic
therapy. The overall postoperative emesis rate was 59.3% in the
placebo group and was reduced to 40% in the scopolamine group
and 41.8% in the ondansetron group, respectively. The authors
evaluated the effects of aforementioned drugs at different time
periods postoperatively (0–2 h, 2–6 h, and 6–24 h), and it was
concluded that the efﬁcacy of scopolamine was higher compared
to ondansetron or placebo during the postoperative 6–24 h inter-
val. The side effects reported during the study did not lead to
discontinuation of drug use in any patient. Dizziness varied sig-
niﬁcantly among the groups, but the relative incidence was not
consistent across the time intervals. Dry mouth was somewhat
more common in the scopolamine group in the 6–24 h interval
(9% in placebo group, 4% in ondansetron group, 19% in scopo-
lamine group). Similarly, blurry vision was more common in the
scopolamine group than placebo at 6–24 h (6% vs. 0%). Lethargy
occurred in < 10% of subjects during all time intervals, and its
frequency did not differ among the groups. The differences in drug
effects at different time periods may be related to the pharmacoki-
netic and pharmacodynamic properties of the drug (Harnett et al.,
2007).
Einarsson et al. (2008) concluded that the TDS signiﬁcantly
reduces the incidence and severity of nausea and vomiting
in the ﬁrst 24 h after gynecologic laparoscopic surgery. They
found a signiﬁcantly higher rate of visual disturbances com-
pared with the placebo group (45.8% vs. 8.3%). Symptoms
of dry mouth were also slightly more common in the scopo-
lamine group, but generally did not seem to be bothersome
to study participants (87.5% vs. 79.2%; Einarsson et al., 2008).
Jones et al. (2006) compared the efﬁcacy of active TDS plus
ondansetron with a placebo patch plus ondansetron in high-risk
patients scheduled to receive a short duration general anesthesia
for no longer than an hour. They found that patients receiv-
ing a combination of TDS and ondansetron reported fewer
incidences (39%) of PONV compared to those who received
ondansetron alone (75%). The most frequently reported side
effect was headache, which has been attributed to ondansetron
(Jones et al., 2006). White et al. (2007) compared a combination
of TDS with droperidol vs. TDS with ondansetron in patient
undergoing major laparoscopic surgeries, the study showed that
both combinations were equally effective in preventing nau-
sea and vomiting during the ﬁrst 72 h of the post-operative
period with a complete response of 41 and 51%, respectively
(White et al., 2007).
Recently, a study by Sah et al. (2009) showed the efﬁcacy of
TDS plus ondansetron vs. placebo patch plus ondansetron on the
incidence of PONV in 126 patients undergoing plastic surgery. A
statistically signiﬁcant reduction in postoperative nausea between
8 and 24 h in patients who received TDS was observed. During
the ﬁrst 4 h, no signiﬁcant difference between the two groups
was revealed, which may be attributed to ondansetron adminis-
tration in both groups. The most common side effect was dry
mouth in 70% of patients in the transdermal group compared
with 63% in the placebo group. Visual disturbance was found
in 15% of the TD group compared to 5% of patients in the
placebo group. Sedation was common and notable in 40% of TD
group vs. 33% of the placebo group, probably related to postop-
erative opioid use (Sah et al., 2009). Gan et al. (2009) conﬁrmed
the previous ﬁndings; they expanded the time of observed effec-
tiveness of TDS with data collected from 0–48 h postoperatively
and included the largest sample size to date. The study exam-
ined active TDS plus ondansetron compared with placebo patch
plus ondansetron as a prophylactic treatment for PONV in 620
female patients undergoing outpatient laparoscopic or breast aug-
mentation surgery. This study found a signiﬁcant reduction in
PONV incidence 24 h after surgery in the group receiving TDS
plus ondansetron compared to the reference group that received
placebo patch plus ondansetron. Despite the fact that TDS has
a slow onset of action, this study showed that the clinical ben-
eﬁts are apparent when TDS is administered in combination
with ondansetron 2 h before induction of anesthesia. In addi-
tion, this trial observed that the overall incidence of adverse
events was less frequent in the group receiving TDS in com-
bination with ondansetron compared with the group receiving
ondansetron alone (36.7% vs. 49%; Gan et al., 2009). The com-
bined use of TDS and dexamethasone by Lee et al. (2010a) showed
that patients undergoing major orthopedic surgery using patient-
controlled analgesia (PCA) was more effective in preventing
PONV compared with dexamethasone alone or dexamethasone
plus ramosetron (47.5% vs. 82.5% and 50.0%, respectively; Lee
et al., 2010a). Limitations of this study include the lack of a control
group without prophylaxis, the 24 h limits of patient evaluation
after surgery, inability to evaluate the drug’s effects on the uri-
nary function because of the presence of an indwelling urinary
catheter (Lee et al., 2010a). Lee et al. (2010a) designed a similar
randomized controlled trial that evaluated the efﬁcacy of prevent-
ing nausea using TDS with ondansetron vs. ondansetron alone
after uterine artery embolization (UAE). The overall incidence of
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nausea after UAE was low; there was a lower level of nausea
in patients treated with TDS compared to the group that did
not receive ondansetron during the ﬁrst 24 h after embolization.
Adverse events were more common with the TDS group, with
twopatients experiencing episodes of profounddisorientation and
71% reporting substantial dry mouth. These results suggest that
although the TDS provides moderate reduction of nausea, its use
is associated with infrequent but notable episodes of patient dis-
orientation.Therefore, the decision whether to use or not a TDS
should be based on careful consideration of the potential bene-
ﬁts vs. the possibility of unwanted side effects for a given practice
setting (Lee et al., 2010b). Green et al. (2012) compared aprepi-
tant alone vs. aprepitant with scopolamine in patients undergoing
elective surgical procedures andwith two ormoreApfel four-point
risk factors. The study showed no difference in complete response
(63% vs. 57%, P = 0.57) between both groups In addition, there
was no difference between the numbers of patients who did not
report any PONV those who used a rescue medication (Green
et al., 2012). Clinical trials with TDS have consistently demon-
strated its safety and efﬁcacy as an antiemetic in many medical
situations that frequently result in severe nausea and vomiting. In
a meta-analysis study, Apfel et al. (2010) revealed a reduced risk of
severe nausea and vomiting in patients receiving TDS compared
to patients receiving placebo. TDS was shown to reduce the risk of
postoperative nausea (relative risk,RR = 0.77; 95%CI, 0.61−0.98;
P = 0.03) Themost prevalent side effect registered at 24–48 h after
surgerywas the occurrence of visual disturbances (RR= 3.35; 95%
CI, 1.78–6.32) (Apfel et al., 2010).
SAFETY AND TOXICITY
Studies have consistently shown that the TDS is safe and well
tolerated initially in patients treated for motion sickness. Later
studies showed its efﬁcacy for prophylaxis of PONV in patients
undergoing various surgical procedures, including abdominal, and
orthopedic. The most common side effects described through-
out the different studies were dry mouth (∼29%), dizziness (less
than 8%), blurred vision (less than 4%), and disorientation (less
than 1%; Package Insert, 2006). TDS is not recommended for
administration in children and should be used with special cau-
tion in patients with pyloric obstruction, intestinal obstruction,
impaired liver, and kidney function, obstructive urinary dysfunc-
tion, and glaucoma. The patch is contraindicated in patients
hypersensitive to scopolamine and other belladonna alkaloids,
as well as plaster allergies (Renner et al., 2005; Package Insert,
2006). In pregnant women, scopolamine should be adminis-
tered only when potential beneﬁts will overweight the risks to
the fetus. Currently, there are not enough data to prove Scopo-
lamine’s safety in pregnant or lactating mothers (Ayromlooi et al.,
1980; Evens and Leopold, 1980; Briggs et al., 1994), although the
drug is considered compatible with nursing and is not consid-
ered teratogenic. Scopolamine toxicity has been described in a
newborn with symptoms such as tachycardia, fever, and lethargy
(Renner et al., 2005).
DISCUSSION
Despite the recognition of PONV as a contributing factor to post-
operative morbidity, it still remains an actual medical problem
necessitating a search for newer therapies. Current PONV risk
stratiﬁcation tools are helpful in providing a semi-quantitative risk
assessment of PONV. Nevertheless, newer approaches and screen-
ing methods are to be developed to better reﬂect the patients’ and
clinicians’ perception of PONV, provide a reliable means of high-
risk patient selection, and reduce the overall impact of this com-
plication on perioperative outcome. PONV pharmacotherapy and
prophylaxis are based onmonotherapy using a single antiemetic or
combinations of several drugs. Multiple clinical trials have proven
the safety and clinical efﬁcacy of the TDS in treatment of PONV
in various patient groups when used as a single drug or in com-
bination with other drugs. TDS may be an effective method of
PONV prophylaxis when applied within 2 h prior to surgery and
anesthesia (Kotelko et al., 1989; Reinhart et al., 1994; Jones et al.,
2006;White et al., 2007; Gan et al., 2009; Sah et al., 2009; Lee et al.,
2010a,b; Green et al., 2012). This can be explained by the fast
release and absorption of the loading dose in the inner layer of the
patch.
The most recent consensus guidelines for the management
of PONV address the issue of providing antiemetic therapy in
those patients in whom prophylaxis has failed. They recommend
that an antiemetic from a different pharmacologic class than
the drug(s) administered for prophylaxis be given (Gan et al.,
2014). They cite that the 5-HT3 antagonist class as being the
only class that have been extensively studied for the treatment
of existing PONV, and that this class should be administered pref-
ererentially if not already given for prophylaxis. The guidelines
also list alternative treatments to treat established PONV includ-
ing dexamethasone, droperidol, or promethazine, and low dose
propofol (Gan et al., 2014). If TDS is selected as a ﬁrst-line agent
for PONV prophylaxis medication, then this would leave more
of the other drug classes available to treat established PONV if
prophylaxis happens to fail. Due to the longer duration and phar-
macokinetic proﬁle, TDS may also be beneﬁcial for prevention of
PDNV, although further studies need to be performed to study this
effect.
In conclusion, an effective management of PONV mandates
understanding the pathophysiological mechanisms of PONV
development and pharmacologic proﬁles of the applied medica-
tions, as well as their interaction with anesthetics, and other drugs
used during the perioperative period. Effective reduction of the
frequency and severity of PONV in various patient groups can be
achievedwith judicioususemono-or combinationpharmacother-
apy or non-pharmacological methods. Current scientiﬁc evidence
indicates that TDS may be effectively used for prophylaxis and
therapy of PONV.
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